Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPRIT Vaccine Substudies (FLUVAC and TEPVAC)
NCT00050726Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2001
- Primary completion
- Apr 2006
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of aldesleukin in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Proportion of patients with seroconversion to one or more vaccine antigens. Started May 2001; status: completed.
02
Drugs
aldesleukin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00050726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050726.